Featured Testing
OnkoMatch Tumor Genotyping by GenPath has just been launched! This assay personalizes cancer by providing, from 1 specimen, a molecular profile across 68 mutations in 14 oncogenes. Many of these oncogenes have targeted therapies either approved or in clinical trials. OnkoMatch technology, based on SNaPshot, has been licensed exclusively from Mass General Hospital and recently written up in the Annals of Oncology.
In The News
In a recent article titled “Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice“, author Dr. Dora Dias-Santagata of Mass General details the study’s findings. “Genotyping for ‘driver mutations’ is becoming increasingly central to oncology care. Broad genotyping has great utility in influencing treatment decisions and directing patients toward relevant clinical trials.”
*Sequest, L.V. et al. Annals of Oncology. 2011; 22: 2616-2624.
*Sequest, L.V. et al. Annals of Oncology. 2011; 22: 2616-2624.